Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Real-world users of triple therapy for asthma in the US
CONCLUSION: In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.PMID:38381542 | DOI:10.37765/ajmc.2024.89494 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - February 21, 2024 Category: Health Management Authors: Nadia N Hansel Carl B Abbott Carlyne M Averell Guillaume Germain Fran çois Laliberté Malena Mahendran Mei S Duh Russell A Settipane Source Type: research
Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease
CONCLUSION: Indirect comparison should be performed via Bayesian approach instead of frequentist inference with a fixed-effect model. Claiming the superiority of a specific medication over other therapies should be confirmed by findings originating from well-designed RCTs.PMID:38318884 | DOI:10.1080/17476348.2024.2316167 (Source: Expert Review of Respiratory Medicine)
Source: Expert Review of Respiratory Medicine - February 6, 2024 Category: Respiratory Medicine Authors: Luigino Calzetta Paola Rogliani Source Type: research
Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
ConclusionPatients with COPD treated with ICS/LABA during baseline, including patients specifically treated with BUD/FORM and those with a history of ≥ 1 exacerbation, had fewer COPD exacerbations and lower COPD-related HCRU after initiating FF/UMEC/VI. (Source: Advances in Therapy)
Source: Advances in Therapy - February 4, 2024 Category: Drugs & Pharmacology Source Type: research
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials
ConclusionsThe availability of individual-level patient data in conjunction with a parametric approach enabled the characterisation of interindividual differences in the patterns of reliever use in patients with moderate-severe asthma. Taken together, individual demographic and clinical characteristics, as well as exacerbation history, can be considered an indicator of the degree of asthma control. High SABA reliever use suggests suboptimal clinical management of patients on maintenance therapy. (Source: Advances in Therapy)
Source: Advances in Therapy - February 1, 2024 Category: Drugs & Pharmacology Source Type: research
Fluticasone Furoate versus Fluticasone Propionate/Azelastine in Moderate-to-Severe Persistent Perennial Allergic Rhinitis from Thai Adult chronic Rhinitis prospective Cohort (TARhiC)
According to the 2-week randomized trials in patients with seasonal allergic rhinitis, intranasal corticosteroid (INCS)/intranasal antihistamine was more effective than INCS monotherapy. However, studies longer than 2-week duration in perennial allergic rhinitis (PAR) comparing their efficacy are limited. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Piyaporn Chokevittaya, Chamard Wongsa, Irin Vichara-Anont, Thanachit Krikeerati, Mongkhon Sompornrattanaphan, Kawita Atipas, Dichapong Kanjanawasee, Triphoom Suwanwech, Pongsakorn Tantilipikorn, Torpong Thongngarm Source Type: research
Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Real-world data characterizing patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) are limited; these data are important to complement findings from more stringent patient populations represented in initial FF/UMEC/VI efficacy studies. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Kristin Wrobleski, Stephen Noorduyn, Lydia Lee, Emmeline Igboekwe, Meixia Liu, Phani Veeranki, Rosirene Paczkowski Source Type: research
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease
Ann Intern Med. 2024 Jan;177(1):eL230428. doi: 10.7326/L23-0428.NO ABSTRACTPMID:38224597 | DOI:10.7326/L23-0428 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 15, 2024 Category: Internal Medicine Authors: Andrew Clerman Markham Luke Source Type: research
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease
Ann Intern Med. 2024 Jan;177(1):eL230429. doi: 10.7326/L23-0429.NO ABSTRACTPMID:38224596 | DOI:10.7326/L23-0429 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 15, 2024 Category: Internal Medicine Authors: William B Feldman Aaron S Kesselheim Jerry Avorn Massimiliano Russo Shirley V Wang Source Type: research
Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β < sub > 2 < /sub > -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis
CONCLUSION: Our findings provide important evidence on the effectiveness and safety of ICS/LABA FDC compared with LAMA for bronchiectasis. BEC/FOR and BUD/FOR were associated with better outcomes than FLU/SAL.PMID:38224017 | DOI:10.1080/17512433.2024.2306218 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - January 15, 2024 Category: Drugs & Pharmacology Authors: Vincent Yi-Fong Su Ting-Lin Ding Yuh-Lih Chang Yueh-Ching Chou Hsuen-En Hwang Chian-Ying Chou Chia-Chen Hsu Source Type: research
